Supplementary Tables 1-7, Figures 1-3 from Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma

Supplementary Table 1. Additional Study Eligibility Criteria. Supplementary Table 2. Pharmacokinetic Serum Sample Collection. Supplementary Table 3. Summary of Adverse Events and Discontinuations. Supplementary Table 4. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 1. Supplementary Table 5. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 12. Supplementary Table 6. Best Overall Response, Objective Response Rate, and Disease Control Rate (FAS). Supplementary Table 7. Summary of ADA Incidence by Actual Dose. Supplementary Figure 1. Study Design for Dose Escalation and Dose Expansion. Supplementary Figure 2. CONSORT diagram. Supplementary Figure 3. Individual CD19+ Nadir Percent Change from Baseline.